This company shares tumbled -36.76% from their most recent record high of $120.46 and now hold $2.46 billion in market value of equity.
The company's stock is now moving with a +ve distance from the 200 day SMA of approximately 3.29%, and has a solid year to date (YTD) performance of 8.77% which means that the stock is constantly adding to its value from the previous fiscal year end price. The company operates in the Healthcare sector with a market capitalization of 101.84 Million. The stock increased 1.35% or $0.86 during the last trading session, reaching $64.67. About 10.48M shares traded or 19.10% up from the average. Sunrun Inc. (NASDAQ:RUN) has declined 16.94% since March 5, 2017 and is downtrending. It has outperformed by 3.59% the S&P500. Moneta Group Investment Advisors Llc sold 4,103 shares as the company's stock declined 8.05% while stock markets rallied. During the same period in the previous year, the company posted $2.70 EPS. The company has a debt-to-equity ratio of 1.53, a quick ratio of 3.48 and a current ratio of 2.74. (NASDAQ:GILD) on Tuesday, March 15 with "Hold" rating. About 3.37M shares traded. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $89.54. It has underperformed by 38.50% the S&P500.
Sphera Funds Management Ltd, which manages about $700.90 million US Long portfolio, decreased its stake in Caesarstone Ltd (NASDAQ:CSTE) by 104,964 shares to 17,833 shares, valued at $531,000 in 2017Q3, according to the filing. Also Streetinsider.com published the news titled: "Form 8-K Sunrun Inc". As per Friday, February 23, the company rating was maintained by BMO Capital Markets. Therefore 67% are positive. Mizuho raised their target price on Gilead Sciences from $77.00 to $83.00 and gave the company a buy rating in a research report on Wednesday, November 8th. Credit Suisse Group set a $80.00 price target on shares of Gilead Sciences and gave the stock a hold rating in a research report on Wednesday, February 7th. Robert W. Baird maintained the stock with "Buy" rating in Thursday, January 18 report. The rating was maintained by Northland Capital with "Hold" on Monday, July 24.
Gilead Sciences, Inc. (GILD)'s Relative Strength Index (RSI) is 44.74. The rating was maintained by Barclays Capital on Tuesday, August 8 with "Overweight". Vetr upgraded shares of Gilead Sciences from a buy rating to a strong-buy rating and set a $91.25 price target for the company in a research report on Monday, February 12th. (NASDAQ:GILD) earned "Buy" rating by Citigroup on Thursday, February 25.
Investors sentiment increased to 1.03 in Q3 2017. Its down 0.23, from 1.03 in 2017Q2. It increased, as 32 investors sold APH shares while 193 reduced holdings. 127 funds opened positions while 474 raised stakes. 292.31 million shares or 0.47% less from 293.69 million shares in 2017Q2 were reported. Axa reported 0.98% in Gilead Sciences, Inc. 1832 Asset Management Limited Partnership has 48,225 shares. Hollow Brook Wealth Management Llc has 84,110 shares for 4.98% of their portfolio.
Lyon Street Capital Llc decreased Quotient Technology Inc stake by 295,813 shares to 498,526 valued at $7.80M in 2017Q3. Domini Impact Invs Ltd holds 4,681 shares or 8.62% of its portfolio. Zacks Investment Management invested in 1.14% or 600,885 shares. Royal State Bank Of Scotland Grp Incorporated Public Ltd Com holds 5.29% or 263,309 shares in its portfolio. 5 analysts say it's a Hold while 0 analysts provided their expert opinion as Sell. Glenmede Na holds 623,506 shares. "Hourly earnings probably slowed a little after a weather-related boost; we believe the trend is up, however", said Jim O'Sullivan of High Frequency Economics in a report. They expect $0.80 EPS, up 12.68% or $0.09 from last year's $0.71 per share. SLM's profit will be $104.04M for 11.69 P/E if the $0.24 EPS becomes a reality. After $0.86 actual EPS reported by Amphenol Corporation for the previous quarter, Wall Street now forecasts -6.98% negative EPS growth. See which 3 stocks are most likely to make moves following their insider activities. The insider Meyers James R sold 100,000 shares worth $8.02 million. Amundi Pioneer Asset Mngmt stated it has 5.91M shares or 1.52% of all its holdings.
Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 90% are positive. Gilead Sciences had 126 analyst reports since July 29, 2015 according to SRatingsIntel. Bank of America maintained it with "Neutral" rating and $86 target in Wednesday, October 4 report.
Gilead Sciences Inc. (GILD)'s distance from 200 day simple moving average is 3.29 percent, its distance from 50 day simple moving average is -1.44 percent, while its distance from 20 day simple moving average is -2.89 percent. The stock has "Buy" rating by Jefferies on Tuesday, October 25. The stock of SLM Corporation (NASDAQ:SLM) has "Outperform" rating given on Friday, December 2 by FBR Capital. The firm has "Market Perform" rating given on Thursday, October 19 by Leerink Swann. The stock of Sunrun Inc. (NASDAQ:GILD) advice their clients to include it in their buy candidate list. (NASDAQ:MGI). Omers Administration Corp accumulated 659,700 shares.
Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 6th. On Friday, January 26 the stock rating was maintained by Needham with "Buy". (NASDAQ:GILD) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The stock was sold at an average price of $78.69, for a total transaction of $1,967,250.00.
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The biopharmaceutical company reported $1.78 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.67 by $0.11. Company fiscal year is ending in December and analysts' consensus recommendation is Outperform for GILD and estimated EPS for next quarter is 1.64.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.